A JAMA study finds that treating elderly patients who have subclinical hypothyroidism does not improve hypothyroid symptoms or fatigue.
A literature review published in JAMA Internal Medicine finds that many medical tests are overused and overtreatment is common and potentially harmful.
In this month's "Endocrine Feedback" column, Dr. Melissa Young explores how her career has evolved over the years and questions what the future may hold.
A 58-year-old man with a history of diabetes mellitus type 1 went to the urgent care after he awoke one morning and noticed the bottom of his foot near his toes felt funny. When he looked at the area, he realized that a bulla had formed on the bottom of his foot overnight. He hadn’t injured or cut the foot or leg recently, and he felt in good health otherwise. What's your diagnosis?
Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
A comprehensive systematic review and meta-analysis of 36 randomized clinical trials shows that using activity trackers produces some health benefit, but primarily when combined with coaching.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.
Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes.
Image IQ: A 60-year-old woman undergoing hemodialysis for chronic kidney disease developes a smooth plaque on her leg. What's your diagnosis?
The cost of treating osteoporosis in the United states has risen 118 percent over the last 19 years, shows an analysis presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.
In new research published in the New England Journal of Medicine, investigators led by William Tamborlane, M.D., a Yale University pediatric endocrinologist, reported the efficacy of the GLP1 agonist liraglutide for children with type 2 diabetes. In this Q&A, Dr. Tamborlane discusses the importance of expanding treatment options.
Men with diabetes may have a higher risk of experiencing chronic lower back pain, say researchers writing in BMJ Open this month.
Normal thyroid stimulating hormone levels don't necessarily stave off all-cause mortality for hypothyroid patients, but adverse outcomes may intensify if levels fall below or above the norm.